Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CerusSTU:CU2 +0.86%78 EV-to-EBITDA is 198.37 as of Aug. 27, 2026. GuruFocus rates STU:CU2 with a GF Score™ of 78/100 and a GF Value™ of €1.97 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 523 Medical Devices & Instruments companies, Cerus ranks worse than 97.9% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cerus's enterprise value is €491.2 Mil.
Cerus's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €2.5 Mil. Therefore, Cerus's EV-to-EBITDA for today is 198.37.
The historical rank and industry rank for Cerus's EV-to-EBITDA or its related term are showing as below:
STU:CU2'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -93.28 Med: -15.94 Max: 1283.79
Current: 197.18
During the past 13 years, the highest EV-to-EBITDA of Cerus was 1283.79. The lowest was -93.28. And the median was -15.94.
STU:CU2's EV-to-EBITDA is ranked worse than 97.9% of 523
companies
in the Medical Devices & Instruments industry
Industry Median: 14.59
vs STU:CU2: 197.18
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-08-27), Cerus's stock price is €2.34.
Cerus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.027. Therefore, Cerus's PE Ratio (TTM) for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cerus's share price for today is €2.34.
Cerus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.027.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Cerus's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:CU2 vs CTKB, TCMD, CBLL: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Cerus's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cerus EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cerus's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cerus's EV-to-EBITDA falls into.
Cerus's current Enterprise Value is €491.2 Mil.
Cerus's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cerus (STU:CU2) has a EV-to-EBITDA of 198.37 as of Aug. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cerus. According to the industry distribution chart, Cerus ranks #512 out of 523 companies in the Medical Devices & Instruments industry, placing it in the top 97.9%.
Is Cerus' EV-to-EBITDA too high?
Cerus' current EV-to-EBITDA is 198.37. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.59. Cerus' value of 198.37 is 1259.6% above this industry median. Based on the distribution chart, Cerus ranks #512 out of 523 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Cerus has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cerus' EV-to-EBITDA compare to CTKB and TCMD?
According to the Medical Devices & Instruments industry distribution chart, Cerus ranks #512 out of 523 companies for EV-to-EBITDA. This places Cerus in the lower half of its industry. The industry median EV-to-EBITDA is 14.59. Cerus' value of 198.37 is 1259.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.59, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cerus's current EV-to-EBITDA of 198.37 is 1259.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cerus. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cerus's current EV-to-EBITDA is 198.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cerus stock overvalued right now?
Based on GuruFocus' analysis, Cerus (STU:CU2) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.97, compared to a current price of €2.34 — trading 18.8% above its estimated fair value. The current EV-to-EBITDA is 198.37 and 1259.6% above the Medical Devices & Instruments industry median of 14.59. Cerus' overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Cerus (STU:CU2), the current EV-to-EBITDA is 198.37 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cerus (STU:CU2) Overvalued in 2026?
Based on GuruFocus' analysis, Cerus stock appears to be overvalued.
The current stock price of €2.34 is trading 18.8% above its estimated GF Value™ of €1.97.
GuruFocus considers Cerus to be Modestly Overvalued.
Key valuation signals for STU:CU2:
EV-to-EBITDA: 198.37
GF Value™: €1.97 vs. price of €2.34 (18.8% above fair value)
Industry Position: 1259.6% above the Medical Devices & Instruments median (#512 of 523)
No single metric tells the full story. See the STU:CU2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
78GF Score
Get the complete analysis for STU:CU2
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CU2 has been successfully added to your 
